The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

Investment Considerations The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic cancer and is advancing toward combination studies with checkpoint inhibitors. A joint venture with GMP Biotechnology enables Oncotelic to conduct low-cost research and development, operate in-house GMP manufacturing, and support a rapidly expanding nanoparticle pipeline trademarked Deciparticle ™. A … Continue reading “Oncotelic Therapeutics Inc. (OTCQB: OTLC)”

View Profile